ArticleCancer cell international2026
Therapeutic profiling of dihydroartemisinin using in vitro and in vivo models reveals anti-glioma potential.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundGlioma constitutes a primary brain tumor with a poor prognosis and survival. The accruing concerns of side effects accompanying the conventional treatment options and chances of tumor relapse have impelled a paradigm shift towards green chemistry for discovering and implementing effective, non-toxic attributes of plant-based products in the medicinal field. We have previously achieved partial rescue of the brain tumor in a Drosophila brain tumor mutant, lethal (2) giant larvae [l(2)gl], using artemisinin and curcumin. In this study, we investigate a key artemisinin derivative, dihydroartemisinin (DHA), using in vitro and in vivo glioma models.
methodsIn vitro drug screening was performed using cell viability, cell cycle analysis, flow cytometry-based apoptosis assay, and immunoblotting to examine the key pathways involved. Subcutaneous and orthotopic murine glioma models were developed, and DHA dosage for administration was standardized. The physiological and behavioral parameters of the animals were monitored, and an in vivo serum biochemical assay was conducted. The extracted samples were subjected to hematoxylin and eosin staining, western blotting, and immunostaining. The findings were compared between the control and the treatment groups.
resultsDHA lowered the proliferation of glioma cells, induced cell cycle arrest at the G0/G1 and G2/M checkpoints in a dose-dependent manner, and promoted apoptosis in vitro. It targeted the Ak strain transforming (AKT) signaling axis by eliciting phospho-AKT (pAKT) inhibition and also induced caspase-3 dependent apoptosis, leading to an effective tumor regression in the subcutaneous flank rat glioma model. The drug delayed tumor invasiveness in the orthotopic glioma models of rat and athymic mice, thus mitigating the disease severity and the associated symptoms. Immunohistochemical analysis in tumors using angiogenesis and proliferation markers showed reduced angiogenesis and proliferative rate post-treatment.
conclusionOur work unveils the therapeutic potential of DHA in modulating glioma progression both in vitro and in vivo. By reprogramming the tumor growth dynamics and targeting key signaling networks involving AKT and caspase-3, DHA may pose as a promising therapeutic candidate for glioma treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.